Since c-Met, PD-L1, MMR protein expression may be readily implemented in an immunohistochemical processing system, the relevant survival results shown in the study may imply that those markers, together with PIK3CA mutation, may be used as prognostic markers in BC. The gene discussed is MRC1; the disease is breast cancer.